- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05806918
Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer
A Multicenter, Randomized, Double-blind, Controlled, Non-inferiority Phase III Clinical Trial of Recombinant Human Interferon Alpha-2b Gel (ZK-A03) in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer
The goal of this clinical trail is to demonstrate the non-inferiority of recombinant human interferon α-2b gel (ZK-A03) after changing the manufacturer of the active ingredient in patients with herpes zoster.
This double-blind study will enroll approximately 368 adult patients with herpes zoster in China. Eligible patients will be assigned randomly at a 1:1 ratio.
For each patient who is included, treatment may last up to 10 days. During the study, subjects will be treated with recombinant human interferon α-2b gel (either before or after the alteration of the active ingredient manufacturer), at a frequency of four times a day, together with a background therapy of valaciclovir hydrochloride.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jinghua Xu, MD
- Phone Number: 021-52887781
- Email: xjhhsyy@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Men and women aged between 18 and 70 years old.
- Diagnosed as herpes zoster.
- Time to appearance of lesions ≤ 72 hours prior to the first dosing (lesions may represent as: erythema, papules or blisters), lesion area ≤ 3% body surface area (BSA).
- Self-rated Numerical Rating Scale (NRS) in pain ≤ 6.
- Negative serum pregnancy test for women of reproductive age. Birth control from first dosing until 1 month after last dosing for all men and women of reproductive age.
- Subjects must have signed an informed consent form (ICF).
Main Exclusion Criteria:
- Diagnosed as herpes zoster on face, visceral herpes zoster, herpes zoster meningitis, disseminated herpes zoster, zoster sine herpete or blood blisters and necrosis.
- The lesion is complicated with other skin diseases that may affect the evaluation of efficacy,
- Skin lesions combined with severe bacterial or fungal infections.
- Use of antiviral or analgesic therapy for herpes zoster within 2 weeks prior to the first dosing.
- Known allergies to recombinant human interferon α-2b and chemical structure analogs, valaciclovir or history of any drug, food or other allergy.
- Liver and/or renal disfunction,ie. Alanine aminotransferase (ALT), Aspartate transaminase (AST) > 2 times of upper normal limit(ULN); Creatinine Clearance Rate (CCR) < 50 L/min.
- Combined with immunodeficiency disease or require long-term glucocorticoid or immunosuppressive drugs.
- Combined with severe cardiovascular, respiratory, gastrointestinal or neurological disorders and remains unstable after treatment.
- History of psychiatric illness or inability to fully comply to the protocol.
- Use of another investigational product within 4 weeks prior to the first dosing.
- Pregnant or lactating women.
- Other conditions deemed by the investigator to be inappropriate for participation in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Recombinant Human Interferon α-2b Gel (After the Alteration)
|
Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
|
Active Comparator: Recombinant Human Interferon α-2b Gel (Before the Alteration)
|
Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical cure rate at visit 4 (Day 7)
Time Frame: 7 Days
|
Clinical cure is defined as all blisters being dry and crustosus without erosion or ulceration.
|
7 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical cure rate at visit 3 (Day 4), and visit 5 (Day 11)
Time Frame: 11 Days
|
Clinical cure is defined as all blisters being dry and crustosus without erosion or ulceration.
|
11 Days
|
Time to which new blisters stop appearing
Time Frame: 11 Days
|
The time from the first day of medication (D1) to the cessation of new blisters.
|
11 Days
|
The time to beginning of crusting.
Time Frame: 11 Days
|
The time from the first day of medication (D1) to the beginning of crusting.
|
11 Days
|
The time to which all blisters are crustosus.
Time Frame: 11 Days
|
The time from the first day of medication (D1) to the crustosus of all blisters.
|
11 Days
|
The pain improvement rate at visit 4 (Day 7)
Time Frame: 7 Days
|
Pain change of ≥1 from baseline is considered as pain improvement.
|
7 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZK-A03-LEES-2023-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Zoster
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineCanada, Spain, Korea, Republic of, United Kingdom, France, Czechia
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Herpes Zoster-related Complications
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Estonia, Canada
-
Ohio State UniversityCompletedHerpes Zoster DiseaseUnited States
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Canada, Belgium
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
-
Tanta UniversityNot yet recruitingAcute Herpes Zoster Pain Managment
-
Northwestern UniversityBausch & Lomb IncorporatedTerminatedHerpes Zoster KeratitisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Centrexion TherapeuticsTerminatedAcute-onset Herpes Zoster PainAustralia
Clinical Trials on Recombinant Human Interferon α-2b Gel (After the Alteration)
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Lee's Pharmaceutical LimitedCompleted
-
Digna Biotech S.L.CompletedChronic Hepatitis C Virus Infection | Genotype 1 | Treatment-Experienced Patients | RelapsesSpain
-
Children's Hospital of Fudan UniversityChanghai Hospital; Hunan Children's Hospital; Yuying Children's Hospital of Wenzhou... and other collaboratorsCompleted
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI); NCIC Clinical Trials Group; Children's Oncology... and other collaboratorsActive, not recruitingMelanoma (Skin)United States, Canada, Australia, South Africa
-
Shanghai Jiao Tong University School of MedicineUnknown2019 Novel Coronavirus InfectionChina
-
Anhui Medical UniversityFirst Affiliated Hospital Bengbu Medical College; The Second Hospital of Anhui... and other collaboratorsRecruiting
-
The First Hospital of Jilin UniversityChinese Academy of SciencesUnknown
-
Junqi NiuChinese Academy of SciencesUnknownLiver Diseases | Hepatitis C, Chronic | Interferon DeficiencyChina